Key facts

Financial results

Total revenue
$24.7bn
↑ 1% at CER

Core earnings per share
$4.26
↑ 7% at CER



SEC filings

SEC filings are those documents that we are required to file by virtue of our listing on the New York Stock Exchange. They contain mainly financial information.

These documents are also available for viewing on the SEC website at www.sec.gov. The Company will send any holder of the Company’s securities, upon request, a hard copy of the Company’s complete audited financial statements free of charge. Requests may be made by writing to:

Company Secretary
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA


Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

138

projects in our pipeline

10

new molecular entities in our late-stage pipeline



Contact us

UK investor enquiries

Main Contacts

UK general enquiries

Thomas Kudsk Larsen

Eugenia Litz

Respiratory, Inflammation & Autoimmunity

Nick Stone

Respiratory & Autoimmunity

Craig Marks

Finance, Fixed Income, M&A

Christer Gruvris

Infection & Neuroscience

US investor enquiries

Main Contacts

Lindsey Trickett

Cardiovascular & Metabolic diseases

Mitchell Chan

Oncology

US general enquiries

  • Annual reports

    Our Annual Report provides a wide range of information about our global business.


  • Our Pipeline

    Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development